Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AddictiStim is a French medical technology company specializing in the development of non-invasive neuromodulation devices for the treatment of substance use disorders. The company's core technology is based on Transcranial Direct Current Stimulation (tDCS), which delivers low-level electrical currents to the dorsolateral prefrontal cortex to modulate neuronal activity and reduce cravings. Their lead product is a wearable headset designed for ease of use in both clinical settings and potentially for home-based therapy. AddictiStim aims to provide a non-pharmacological alternative for patients struggling with tobacco and alcohol addiction, addressing a significant unmet need in mental health. The company is currently advancing its clinical programs through multi-center trials to establish the efficacy and safety of its neuromodulation platform.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on AddictiStim.